Drug
CM082
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
0(0%)
Phase Distribution
Ph phase_3
1
20%
Ph phase_1
3
60%
Ph phase_2
1
20%
Phase Distribution
3
Early Stage
1
Mid Stage
1
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
3(60.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
1(20.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Other(5)
Detailed Status
unknown4
Suspended1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
N/A
Most Advanced
Phase 3
Trials by Phase
Phase 13 (60.0%)
Phase 21 (20.0%)
Phase 31 (20.0%)
Trials by Status
unknown480%
suspended120%
Recent Activity
0 active trials
Showing 5 of 5
unknownphase_1
Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid Tumors
NCT03792958
suspendedphase_1
CM082 in Patients With Myopic Choroidal Neovascularization (CNV)
NCT04222842
unknownphase_3
CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinoma
NCT03095040
unknownphase_2
Safety and Tolerability of Oral CM082 in Patients With wAMD
NCT03710863
unknownphase_1
Study of the Combination of CM082 With Everolimus in Patients With mRCC
NCT02577458
Clinical Trials (5)
Showing 5 of 5 trials
NCT03792958Phase 1
Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid Tumors
NCT04222842Phase 1
CM082 in Patients With Myopic Choroidal Neovascularization (CNV)
NCT03095040Phase 3
CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinoma
NCT03710863Phase 2
Safety and Tolerability of Oral CM082 in Patients With wAMD
NCT02577458Phase 1
Study of the Combination of CM082 With Everolimus in Patients With mRCC
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5